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Background:  Atrial  ﬁbrillation  (AF)  increases  the risks  of stroke  and  death,  and  the  prevalence  of  AF is
increasing  signiﬁcantly.  Until  recently,  warfarin  was  the  only  oral  anticoagulant  for stroke  prevention,
but  novel  anticoagulants  are  now  under  development.
Methods and results:  The  Fushimi  AF  Registry  is  a  community-based  survey  of  AF  patients.  We  aimed
to  enroll  all of  the  AF  patients  in  Fushimi-ku,  which  is  located  at the  southern  end  of  the city  of Kyoto.
Fushimi-ku  is  densely  populated  with  a total  population  of  283,000,  and  is  assumed  to  represent  a typ-
ical urban  community  in  Japan.  On  the  basis  of  the  general  prevalence  of AF  in  the  Japanese  (0.6%),  we
estimated  the  total  number  of AF  patients  as  1700.  A total  of  76  institutions,  a large  proportion  of  which
were  private  clinics,  participated  in the  study.  At  present,  we  have  enrolled  3183 patients  from March
2011  to June  2012  (approximately  1.12%  of  total  population).  The  mean  age  was  74.2  ±  11.0  years,  and
59.3%  of  subjects  were  male.  The  mean  body  weight  was  58.5  ±  13.2 kg,  and  the  proportions  with a body
weight  of less  than  50  kg and  60  kg were  25.7%  and  55.0%,  respectively.  The  type  of  AF was  paroxys-
mal  in  46.0%,  persistent  in  7.3%,  and permanent  in  46.7%.  Major  co-existing  diseases  were  hypertension
(60.6%),  heart  failure  (27.9%),  diabetes  (23.2%),  stroke  (19.4%),  coronary  artery  disease  (15.0%),  myocardial
infarction  (6.4%),  dyslipidemia  (42.4%),  and  chronic  kidney  disease  (26.4%).  The  mean  CHADS2  score  was
2.09 ± 1.35:  0  in  11.8%  of  patients,  1 in  27.1%,  and  2 in  29.1%.  Warfarin  was  prescribed  in only  48.5%  of
patients,  whereas  anti-platelet  drugs,  mainly  aspirin,  were  prescribed  for more  than  30%  of  the  patients.
Conclusions:  The  Fushimi  AF  Registry  provides  a unique  snapshot  of  current  AF  management  in  an  urban
3  Jap
community  in  Japan.
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Atrial ﬁbrillation (AF) is the most common cardiac arrhyth-
ia  in developed countries, and increases the risks for stroke and
eath [1].  The number of patients with AF is gradually and steadily
ncreasing in Japan because of the aging of the Japanese population
2].
The Fushimi AF Registry is a community-based survey of AF
atients. In this registry, we aimed to enroll all the AF patients in
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Fushimi-ku. Fushimi-ku is located at the southern end of the city
of Kyoto and is one of its eleven wards; it has prospered through
various types of business and industry, and was therefore assumed
to represent a typical urban community in Japan. In fact, the age
distribution of the population in Fushimi-ku is similar to that in
the city of Kyoto, as well as that in Japan. Fushimi-ku is densely
populated, with a total population of 283,000. On the basis of the
general prevalence of AF in the Japanese (0.6%) [3],  a rough estimate
of the number of patients with AF in Fushimi-ku is 1700. However,
taking into consideration that many of the patients with AF are
asymptomatic, we  assumed that the actual prevalence of AF might
be even higher.
Vitamin K antagonists (mainly warfarin) are highly effective to
reduce the risk of stroke, and have been the sole choice for stroke
prevention during the last 50 years; however, their use is limited
vier Ltd. All rights reserved.
 Cardio
f
i
o
s
[
t
o
c
t
p
d
e
p
c
M
A
t
I
T
z
1
c
p
w
n
t
v
c
r
e
c
o
c
D
p
c
t
p
o
C
p
h
i
d
The prevalence of the types of AF varied between the ageM. Akao et al. / Journal of
or a number of reasons: narrow therapeutic range, drug and food
nteractions, need for monitoring, and risk of bleeding [4].  Novel
ral anticoagulants have recently been shown to be equivalent or
uperior to warfarin in preventing stroke or systemic embolism
5–7]. These new-generation drugs may  provide better alternatives
o warfarin for stroke prevention in patients with AF.
The purpose of this study is to demonstrate the current status
f the clinical background of AF patients in a community-based
linical setting. In the Fushimi AF Registry, a total of 76 institu-
ions, a large proportion of which were private clinics of general
ractitioners, participated in the registry. Most of the previous epi-
emiological data on AF were derived from databases of patients
nrolled at highly specialized cardiovascular centers, but many AF
atients are under the management of primary-care physicians in
ommunity-based clinical settings.
ethods
The inclusion criterion for the registry is the documentation of
F on 12-lead electrocardiogram (ECG) or Holter monitoring at any
ime. There are no exclusion criteria.
A total of 76 institutions, all of which are members of Fushimi-
shikai (Fushimi Medical Association), participated in the registry.
hey consist of 2 cardiovascular centers (National Hospital Organi-
ation Kyoto Medical Center and Ijinkai Takeda General Hospital),
0 small- and medium-sized hospitals (<400 beds), and 64 primary
are clinics.
The enrollment of patients was started in March 2011. All the
articipating institutions tried to enroll all consecutive patients
ith AF under regular outpatient care or under admission. We  did
ot include the address of patients as an inclusion or exclusion cri-
erion; this database is the accumulation of the AF patients who
isited the participating medical institutions in Fushimi-ku.
Clinical background data, including underlying diseases, medi-
ations, and laboratory data, were collected using an electronic case
eport form of a web-based database system (https://edmsweb16.
ps.co.jp/edmsweb/002001/FAF/top.html). Data were automati-
ally checked for missing or contradictory entries and values out
f the normal range. Additional editing checks were performed by
linical research coordinators at the general ofﬁce of the registry.
ata collected at the registry are expressed as mean ± SD.
Patients were categorized into three clinical types of AF:
aroxysmal, persistent, or permanent, based on the physician’s per-
eption of the AF at the time of enrollment. The deﬁnitions of the
ypes of AF are as follows:
Paroxysmal AF:  Recurrent AF that terminates spontaneously and
lasts ≤7 days;
Persistent AF:  recurrent AF or sustained AF lasting >7 days that
can be terminated by either pharmacological therapy or electrical
cardioversion;
Permanent AF: AF that has been present for a long time. Pharmaco-
logical or electrical cardioversion has not been performed, or one
or several attempts have failed to restore sinus rhythm.
A patient with ﬁrst-diagnosed episode of AF was  followed for a
eriod of time before the registration, and was classiﬁed into one
f the above-mentioned three types of AF.
The risk of stroke was evaluated by CHADS2 score [8] and
HA2DS2-VASc score [9].
Heart failure was diagnosed if the patient had a history of hos-italization for heart failure, if the patient had symptoms due to
eart failure (New York Heart Association functional class ≥2), or
f the left ventricular ejection fraction was <40%. Hypertension was
iagnosed if peripheral blood pressure was >140/90 mmHg  or iflogy 61 (2013) 260–266 261
the patient was taking medication for hypertension. The presence
of diabetes was  diagnosed using HbA1c (JDS) 6.5% as the standard
or was  assumed if the patient was  taking medication for the
treatment of diabetes. Dyslipidemia was  diagnosed if total choles-
terol was  >220 mg/dL, if low-density lipoprotein cholesterol was
>140 mg/dL, if triglyceride was  >150 mg/dL, if high-density lipopro-
tein cholesterol was <40 mg/dL, or if the patient was taking statins.
Chronic kidney disease (CKD) was  diagnosed if there was persis-
tent proteinuria or if estimated glomerular ﬁltration rate (eGFR)
was <60 mL/min/1.73 m2 for more than 3 months. Major bleed-
ing was deﬁned as a reduction in the hemoglobin level of at least
2 g/dL, transfusion of at least 2 units of blood, or symptomatic bleed-
ing in a critical area or organ. All other bleeding was  considered
minor.
The study protocol was  approved by the ethical committees of
National Hospital Organization Kyoto Medical Center and Ijinkai
Takeda General Hospital. Since the present research belongs to an
observational study not using human biological specimens, written
informed consent was not obtained from each patient according
to the ethical guidelines for epidemiological research issued by
Ministry of Education, Culture, Sports, Science and Technology and
Ministry of Health, Labour and Welfare, Japan. However, we  have
published all relevant details regarding this study to be carried out
and provide each patient an opportunity to refuse inclusion in this
research by posting the details at every participating clinic and at
the homepages of our institutions. We  also held a public meeting
with citizens in Fushimi-ku to demonstrate outlines of the present
study.
Results
As of June 2012, we  have enrolled 3183 patients from 76 insti-
tutions (Appendix A), which is more than we anticipated from the
population size; 2317 patients were enrolled from cardiovascular
centers and 866 from small- or medium-sized hospitals or primary
care clinics.
Baseline characteristics of registered patients
The baseline clinical characteristics of all registered AF patients
are summarized in Table 1; 59.3% were male, and the mean age
was 74.2 years. The type of AF was paroxysmal in 46.0%, persis-
tent in 7.3%, and permanent in 46.7%. Compared with studies in
Europe or North America, the Japanese patients were much leaner
and smaller; the proportions with a body weight of less than 50 kg
and 60 kg were 25.7% and 55.0%, respectively. Almost half of the
patients were asymptomatic. Table 2 shows co-morbidities. Hyper-
tension was  by far the most prevalent associated medical condition,
exceeding 60%. Other risk factors for atherosclerotic diseases were
remarkably frequent: 23.2% of patients were diabetic, 42.4% had
dyslipidemia, and 26.4% had CKD. Coronary artery disease and
heart failure were present in 15.0% and 27.9%, respectively. Of
all patients, 21.9% had previously suffered from stroke, transient
ischemic attack (TIA), or systemic embolic events, and the vast
majority of these cases were of ischemic stroke (17.8%). A small
number (1.7%) of patients had a history of major bleeding, and 8.6%
had undergone pacemaker device implantation.
Age groups and types of AFgroups (Fig. 1). Paroxysmal AF was  the predominant type in the
younger patients, but the proportions with persistent/permanent
AF increased with increasing age, and more than 50% of patients
had persistent/permanent AF among those ≥70 years old.
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Table  1
Baseline characteristics of the patients.
n 3183
Male (%) 1887 (59.3%)
Age (years) 74.2 ± 11.0
20–29 7 (0.2%)
30–39 21 (0.7%)
40–49 66 (2.1%)
50–59 159 (5.0%)
60–69 711 (22.3%)
70–79 1163 (36.5%)
80–89 870 (27.3%)
90– 186 (5.8%)
≥70 2219 (69.7%)
≥75 1708 (53.7%)
≥80 1056 (33.2%)
Range 21–104
Type of atrial ﬁbrillation
Paroxysmal 1463 (46.0%)
Persistent 233 (7.3%)
Permanent 1487 (46.7%)
Height (cm) 159.6 ± 10.1
Weight (kg) 58.5 ± 13.2
<50 699 (25.7%)
<60 1493 (55.0%)
Body mass index (kg/m2) 22.8 ± 3.9
<18.5 320 (12.2%)
18.5–25 1619 (61.6%)
≥25 691 (26.3%)
Systolic BP (mmHg) 124.7 ± 19.1
Diastolic BP (mmHg) 70.3 ± 12.9
Heart rate (bpm) 77.8 ± 15.6
Asymptomatic 1602 (50.3%)
Symptomatic 1581 (49.7%)
Palpitation 1096 (34.4%)
Shortness of breath 474 (14.9%)
Easy fatigue 326 (10.2%)
Chest pain 87 (2.7%)
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Table 2
Co-morbidities.
Stroke/TIA/SEE 697 (21.9%)
Stroke 619 (19.4%)
Ischemic 566 (17.8%)
Hemorrhagic 57 (1.8%)
Unknown 9 (0.3%)
TIA  75 (2.4%)
SEE 40 (1.3%)
Upper limbs 2 (0.1%)
Lower limbs 15 (0.5%)
Coronary artery 4 (0.1%)
Renal artery 5 (0.2%)
Eye 3 (0.1%)
Pulmonary 5 (0.2%)
Others 7 (0.2%)
Heart failure 889 (27.9%)
Hospitalization 536 (16.8%)
NYHA ≥ 2 505 (15.9%)
EF  < 40% 144 (4.5%)
Valvular heart disease 576 (18.1%)
Mitral stenosis 45 (1.4%)
Valve surgery 146 (4.6%)
Cardiomyopathy 95 (3.0%)
Hypertrophic 37 (1.2%)
Dilated 53 (1.7%)
Others 5 (0.2%)
Hypertension 1928 (60.6%)
Diabetes mellitus 737 (23.2%)
Dyslipidemia 1350 (42.4%)
Coronary artery disease 479 (15.0%)
Previous myocardial infarction 203 (6.4%)
Previous PCI 241 (7.6%)
Previous CABG 88 (2.8%)
Peripheral artery disease 138 (4.3%)
Previous PTA 53 (1.7%)
Previous bypass surgery 21 (0.7%)
Chronic kidney disease 841 (26.4%)
Hemodialysis 93 (2.9%)
COPD 156 (4.9%)
Major bleeding 55 (1.7%)
Device implantation 273 (8.6%)
Pacemaker 238 (7.5%)
ICD  18 (0.6%)
CRT 7 (0.2%)
CRT-D 10 (0.3%)
Data are number (%). TIA, transient ischemic attack; SEE, systemic embolic events;
NYHA, New York Heart Association functional class; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass grafting; PTA, percutaneous translu-
minal angioplasty; COPD, chronic obstructive pulmonary disease; ICD, implantable
patients had a creatinine clearance <30 mL/min. Echocardiogra-Faintness 173 (5.4%)
ata are number (%) or mean ± SD; BP, blood pressure.
HADS2 score and stroke risk
Table 3 shows the CHADS2 score and the CHA2DS2-VASc
core. The mean CHADS2 and CHA2DS2-VASc scores were 2.09
nd 3.43, respectively. Fig. 2 shows a histogram of CHADS2 and
HA2DS2-VASc scores. CHADS2 score = 2 was the most common
ubpopulation (Fig. 2A). With increasing age, CHADS2 score grad-
ally increased as well, and patients with a CHADS2 score ≥2
onstituted more than 70% in elderly patients (≥70 years old).
rugs used in AF patients
Table 4 shows the drugs prescribed at baseline. Anticoagulation
rugs, mostly warfarin, were prescribed for 50.5%. Anti-platelet
rugs, including aspirin, were prescribed for more than 30% of
he patients in the registry. Many patients were taking multiple
nti-thrombotic drugs. A combination of warfarin and aspirin was
rescribed to a total of 10.4% of patients.
Rate control drugs were used in 45.5%; more than half of them
ere beta blockers. Rhythm control drugs were used in 20.3%,
ainly class Ic anti-arrhythmic drugs. Since many patients had
o-existing hypertension, anti-hypertensive drugs were widely
rescribed. Angiotensin receptor blockers were the most com-
only used class of anti-hypertensive drugs. Catheter ablation
nd electronic deﬁbrillation were performed in 5.3% and 3.2% of
atients, respectively. Here, the procedures performed for other
rrhythmias (such as paroxysmal supraventricular tachycardia)
ere not included.
Fig. 3 shows the distribution of warfarin and aspirin therapies
ccording to CHADS2 score, age of the patients, and the type of AF. Incardioverter deﬁbrillator; CRT, cardiac resynchronization therapy; CRT-D, cardiac
resynchronization therapy with deﬁbrillator.
the current guidelines, warfarin is recommended for patients with
CHADS2 score ≥2, but warfarin was underused for those high-risk
patients, and also overused for low- to intermediate-risk patients
with CHADS2 score 0–1 (Fig. 3A). Use of warfarin increased as
CHADS2 score increased, but reached a plateau at CHADS2 score
≥4. In the same way, use of warfarin increased with increasing age,
but declined in the over-80s (Fig. 3B). The rate of warfarin pre-
scription was  lower in paroxysmal-type AF than in persistent or
permanent AF, in all CHADS2 score subclasses (Fig. 3C).
Examination results in AF patients
Table 5 shows the examination data. A total of 17.9% of patients
were anemic (hemoglobin <11 mg/dL). Mean eGFR and creatinine
clearance levels were 60.9 and 63.4, respectively and 11.4% ofphy was  performed in 2453 patients: left ventricular end-diastolic
diameter/end-systolic diameter 46.6/30.6, left ventricular ejection
fraction 63.1%, left atrial diameter 43.9 mm.  Left ventricular asyn-
ergy was detected in 23.1% of patients.
M. Akao et al. / Journal of Cardiology 61 (2013) 260–266 263
A
B
0 
200 
400 
600 
800 
1,000  
1,200  
parox ysmal
persistent
permanent
0%
20%
40%
60%
80%
100%
parox ysmal
persistent
permanent
Fig. 1. Age groups and types of atrial ﬁbrillation (A and B).
Table 3
CHADS2 and CHA2DS2-VASc scores.
CHADS2 score 2.09 ± 1.35
0 357 (11.2%)
1 817 (25.7%)
2 880 (27.6%)
3  617 (19.4%)
4  352 (11.1%)
5  142 (4.5%)
6  18 (0.6%)
CHA2DS2-VASc score 3.43 ± 1.71
0 129 (4.1%)
1 313 (9.8%)
2  510 (16.0%)
3  704 (22.1%)
4  686 (21.6%)
5 484 (15.2%)
6 232 (7.3%)
7 100 (3.1%)
8  24 (0.8%)
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Fig. 2. The histograms of CHADS2 (A) and CHA2DS2-VASc9 1 (0.0%)
Data are number (%) or mean ± SD.
Discussion
The Fushimi AF Registry provides a unique snapshot of cur-
rent AF management in an urban community in Japan. The registry
demonstrates that the AF patients have higher risk proﬁles and
receive a lower level of anticoagulation drugs for stroke prevention
than previously reported.
Fushimi-ku is a typical urban district in Japan, located in the
south of the city of Kyoto; it has prospered from a variety of busi-
ness and industry, and is also famous for its historical heritage and
culture spots. It has a population of 283,000, making it the largest
among the eleven wards of Kyoto. The age distribution of Fushimi-
ku is similar to that of Kyoto city, as well as that of the entire
country.
Since many AF patients are asymptomatic and have episodes of
AF intermittently, comprehensive data on the clinical proﬁles of AF
0%
20%
40%
60%
80%
00%
6
5
4
3
2
1
0
0%
5%
0%
5%
0%
5%
0 1 2 3 4 5 6 7 8 9
CHA2DS2 -VASc  sc ore
 (B) scores. Age groups and CHADS2 score (C and D).
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Table  4
Drugs and treatment.
Anti-coagulation drugs 1609 (50.5%)
Warfarin 1543 (48.5%)
Dabigatran (300 mg)  21 (0.7%)
Dabigatran (220 mg) 45 (1.4%)
Dabigatran 66 (2.1%)
Anti-platelet drugs 990 (31.1%)
Aspirin 833 (26.2%)
Clopidogrel 131 (4.1%)
Ticlopidine 60 (1.9%)
Cilostazol 94 (3.0%)
Others 37 (1.2%)
Rate-control drugs 1447 (45.5%)
Digitalis 470 (14.8%)
Verapamil 344 (10.8%)
Diltiazem 119(3.7%)
 blockers 846 (26.6%)
Rhythm-control drugs 646 (20.3%)
Class Ia 178 (5.6%)
Class Ib 31 (1.0%)
Class Ic 412 (12.9%)
Amiodarone 16 (0.5%)
Bepridil 49 (1.5%)
Anti-hypertensive drugs 1743 (54.8%)
ARB 1127 (35.4%)
ACEI 292 (9.2%)
Aliskiren 6 (0.2%)
Eplerenone 31 (1.0%)
CCB  954 (30.0%)
Diuretics 915 (28.7%)
Loop 733 (23.0%)
Spironolactone 322 (10.1%)
Thiazides 125 (3.9%)
Statins 709 (22.3%)
Ethyl icosapentate 43 (1.4%)
Insulin 103 (3.2%)
Oral hypoglycemic drugs 298 (9.4%)
Catheter ablation 168 (5.3%)
Electronic deﬁbrillation 101 (3.2%)
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Fig. 3. Distribution of anti-thrombotic therapies, according to CHADS2 score (A)ata are number (%). ARB, angiotensin receptor blockers; ACEI, angiotensin convert-
ng enzyme inhibitors; CCB, calcium channel blockers.
atients in Japan have not been fully characterized. The prevalence
f AF in the Japanese general population is reportedly 0.6%, based on
he data from periodic health examinations in 2003 [3].  Since that
tudy was based on the data obtained from periodic health exami-
ation and not from the medical records of hospitals or clinics, the
resence of paroxysmal type of AF may  have been underestimated.
ndeed, the Fushimi AF Registry data suggest that the prevalence of
F in Japanese may  have already exceeded 1.0%.
We compared our data with the J-RHYTHM Registry [10,11],
he largest database of Japanese AF patients. In the Fushimi AF
egistry, a total of 76 institutions, a large proportion of which
ere private clinics of general practitioners, participated in the
tudy. In contrast, the J-RHYTHM Registry recruited patients only
rom highly specialized cardiovascular centers or clinics through-
ut Japan, and not from general practitioner clinics. Therefore, it
s assumed that the registered patients in the J-RHYTHM Registry
ere a highly selected class of patients. The Fushimi AF patients
ere older than the J-RHYTHM patients: 74 versus 69 years in terms
f mean age. In particular, the proportion of patients aged over 80
ears was much greater in the Fushimi AF (33.2% vs. 16.0%). Various
o-morbidities were more prevalent in Fushimi AF: hypertension
60.6% vs. 59.1%), diabetes (23.2% vs. 18.2%), stroke/TIA (21.9% vs.
4.0%), and coronary artery disease (15.0% vs. 10.1%). As a result, the
HADS2 score was substantially higher in Fushimi AF: 2.1 versus
.7. In J-RHYTHM, the proportion with a low- to intermediate-risk
HADS2 score of 0–1 was almost 50%, and CHADS 1 was the most
requent subclass; however, in the Fushimi AF, the proportion with
 CHADS2 score 0–1 was 38.9%, and CHADS 2 was the most common
ype. Despite the higher risk proﬁles in the Fushimi AF patients, theyand  age groups (B). Rate of warfarin prescription in each type of atrial ﬁbrillation,
according to CHADS2 score (C).
received warfarin prescriptions at a much lower rate: 48.5% (war-
farin or dabigatran 50.5%) vs. 89%. Thus, the Fushimi AF patients
were older, had higher risk proﬁles with more co-morbidities, but
received warfarin prescriptions at a lower rate.
Warfarin is difﬁcult to use for a number of reasons: narrow
therapeutic range, drug and food interactions, the need for mon-
itoring, and a risk of bleeding [4]. Therefore, it is underused, as
shown in this study, or aspirin is prescribed in many cases as a
substitute for warfarin. The current Japanese guidelines for the
pharmacological management of AF [12,13] do not recommend
aspirin use, on the basis of the results of the JAST study [14] in
which aspirin was neither effective nor safe in AF patients. A previ-
ous study revealed that patients with paroxysmal AF have a risk
of thromboembolic events similar to that in patients with sus-
tained (persistent or permanent) AF [15], and current guidelines
recommend the use of warfarin irrespective of the type of AF. How-
ever, the rate of warfarin prescription was  considerably lower in
paroxysmal AF. Thus, discordance between the guidelines and real-
world clinical practice was  found for several issues, especially in
stroke prevention, but this is not limited to Fushimi-ku: it was
also the case in another cohort study in Japan [16], as well as in
other countries [17–19].  Guideline nonadherence and undertreat-
ment with antithrombotic agents are suggested to be associated
with a high risk of stroke and mortality [20]. These limitations of
M. Akao et al. / Journal of Cardio
Table  5
Examination results.
No. performed
Blood test 2995
White blood cell (/L) 6060 ± 2348 2965
Platelet (×104/L) 20.1 ± 7.0 2957
Hemoglobin (g/dL) 12.9 ± 2.1 2965
Hematocrit (%) 38.7 ± 5.9 2952
Anemia (n) 509 (17.0%)
NT-pro BNP (pg/mL) 1914 ± 5193 746
BNP (pg/mL) 245 ± 967 454
Creatinine (mg/dL) 1.09 ± 1.19 2955
BUN (mg/dL) 20.4 ± 11.5 2906
eGFR (mL/min/1.73 m2) 60.9 ± 24.0 2955
<60 1458 (49.3%)
≥60 1497 (50.7%)
Creatinine clearance (mL/min) 63.4 ± 31.6 2579
<30 294 (11.4%)
30–50 625 (24.2%)
≥50 1660 (64.4%)
Total cholesterol (mg/dL) 179 ± 39 1950
Triglycerides (mg/dL) 126 ± 100 2489
HDL cholesterol (mg/dL) 57 ± 17 2249
LDL cholesterol (mg/dL) 105 ± 32 2158
Glucose (mg/dL) 117 ± 41 2826
HbA1c (JDS) (%) 5.9 ± 2.5 1597
Chest X-ray 2644
CTR (%) 54.5 ± 7.5 2615
Echocardiography 2453
LV  diastolic diameter (mm) 46.6 ± 6.6 2388
LV  systolic diameter (mm)  30.6 ± 7.0 2365
LV  ejection fraction (%) 63.1 ± 11.7 2406
IVS  thickness (mm) 9.5 ± 1.8 2360
PW thickness (mm)  9.4 ± 1.6 2356
LA  diameter (mm) 43.9 ± 8.6 2377
Local asynergy 564 (23.1%) 2441
Data are number (%) or mean ± SD. Anemia was deﬁned as hemoglobin level
<11.0 g/dL. BNP, brain natriuretic peptide; BUN, blood urea nitrogen; eGFR, esti-
mated glomerular ﬁltration rate; HDL, high-density lipoprotein; LDL, low-density
l
v
w
l
d
a
T
e
a
s
i
s
S
(
H
P
D
A
d
Fipoprotein; Hb, hemoglobin; CTR, cardio-thoracic ratio; LV, left ventricle; IVS, inter-
entricular septum; PW,  posterior wall; LA, left atrium.
arfarin have encouraged efforts to develop new oral anticoagu-
ants that are effective, safe, and convenient to use [21]. In Japan,
abigatran and rivaroxaban have been approved and become avail-
ble, and apixaban and edoxaban are now under development.
he Fushimi AF Registry is expected to reveal the balance between
ffectiveness and risk before and after the appearance of the new
nticoagulants.
In conclusion, the Fushimi AF Registry provides a unique snap-
hot of current real-world AF management in an urban community
n Japan. Our ultimate goal is to minimize the occurrence of embolic
troke in AF patients.
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Appendix A.
The following is a list of the institutions participating in the
registry.
Chief investigator: Akao M (National Hospital Organization
Kyoto Medical Center).
Vice-chief investigator: Chun YH (Ijinkai Takeda General Hospi-
tal).
Steering committee: Esato M (Ijinkai Takeda General Hospital),
Abe M (National Hospital Organization Kyoto Medical Center), Tsuji
H (Tsuji Clinic), Furuke K (Furuke Clinic).
Statistical analysis: Wada H (National Hospital Organization
Kyoto Medical Center).
Participating institutions: Department of Cardiology, National
Hospital Organization Kyoto Medical Center (Akao M,  Abe M,
Ogawa H, Masunaga N, Iguchi M,  Ishii M,  Unoki T, Takabayashi
K, Hamatani Y, Yamashita Y, Osakada G, Nakashima Y, Kanasaki
M, Nakano T, Funatsu J, Nishio M,  Takenaka Y); Department of
Arrhythmia, Ijinkai Takeda General Hospital (Chun YH, Esato M,
Kida Y, Nishina N); Koujinkai Oshima Hospital (Terada K); Division
of Translational Research, National Hospital Organization Kyoto
Medical Center (Hasegawa K, Wada H); Kanai Hospital (Nishio
M,  Kamiya Y, Abe M,  Ishii M);  Tsuji clinic (Tsuji H); Furukawa
Medical Clinic (Furukawa K); Nishikawa Clinic (Nishikawa M);
Taniguchi Clinic (Taniguchi Y); Gushiken Clinic (Gushiken T);
Fushimi Shimizu Hospital (Hirata Y); Yoda Clinic (Yoda J); Tasato
Clinic (Tasato H); Ogawa Medical Ofﬁce (Ogawa T); Saiwai Hospital
(Wakatsuki Y, Yahata M,  Higashitani N); Itoh Hemodialysis Clinic
(Itoh H); Itoh Clinic (Itoh H, Ohmori Y); Ryokuhoukai Tsuji Clinic
(Tsuji K); Kitamura Clinic (Kitamura S); Izumikawa Clinic (Izu-
mikawa F); Hirota Clinic (Hirota N); Kyomachi-Oota Clinic (Oota
K); Kouseikai Rehabilitation Clinic (Kou K); Inariyama Hospital
(Tanaka T, Iguchi M);  Matsushita Clinic (Matsushita N); Kitani Clinic
(Kitani K); Kimura Clinic (Kimura F); Hayashi Clinic (Hayashi S);
Handa Clinic (Handa S); Soseikai General Hospital (Hasegawa S,
Kono T, Otsuka K, Soyama A, Okamoto J, Nakai Y); Asamoto Clinic
(Asamoto H); Sugano Clinic (Tanaka H, Murata T); Kyoto Ohashi
General Hospital (Kayawake S, Kinoshita Y); Furuke Clinic (Furuke
K); Kanehisa Clinic (Asano N); Tahara Clinic (Tahara K); Matsumoto
Medical Ofﬁce (Matsumoto K); Kuroda Clinic (Kuroda O); Ochiai
Clinic (Ochiai K, Ochiai J); Fujii Clinic (Fujii M);  Kurihara Clinic
(Kurihara M);  Kuzuyama Clinic (Ito A); Kenkokai Fushimi Clinic
(Totsuzaki S); Nakayama Orthopedic Clinic (Nakayama H); Depart-
ment of Cardiovascular Medicine, Ijinkai Takeda General Hospital
(Kawai C, Hashimoto T, Kakio T, Watanabe C, Takeda S, Sasaki
Y, Shirasawa K, Beppu K, Inoue T, Shirasaka A, Doi T); Tatsumi
Clinic (Ueda T); Oishi Clinic (Oishi M);  Koizumi Clinic (Kasahara A);
Kishida Clinic (Kishida S); Shibata Clinic (Shibata M);  Shimizu Clinic
(Shimizu J); Shirasu Clinic (Shirasu M);  Fujinokai Clinic (Tateishi S);
Tsukuda Clinic (Tsukuda N); Shinseikai Tsuji Clinic (Tsuji K); Nishi
Clinic (Nishi T); Nishimura Clinic (Nishimura S); Haba Clinic (Haba
T); Higashimae Clinic (Higashimae R); Fujimori Clinic (Fujimori C);
Hotta Clinic (Hotta T); Matsui Clinic (Matsui H, Matsui H); Shadan
Matsumoto Clinic (Matsumoto H); Maruo Clinic (Maruo N); Misu
Clinic (Mikami M);  Mekata Clinic (Mekata H); Mori Pediatric Clinic
(Mori H); Wakabayashi Clinic (Wakabayashi M);  Nakatsugawa
Clinic (Sasaki Z); Shiseikai Nishimura Clinic (Nishimura S); Yuge Eye
Clinic (Yuge K); Gokita Hospital (Haruta M);  Soseikai Clinic (Tsuda
E); Toujinkai Hospital (Nishimura M);  Kouno Clinic (Kouno T); Mat-
sumura Clinic (Matsumura S); Fujita Clinic (Fujita A); Takayasu
Clinic (Takayasu F, Takayasu S).References
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